Clinical Trial Update: Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD

View source ↗

Summary

Clinical trial update on monoclonal antibody therapies for AQP4-positive neuromyelitis optica spectrum disorder, with recruitment ongoing at Tongji Hospital.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Snippet

Sponsor: Tongji Hospital | Conditions: NMO Spectrum Disorder | Status: RECRUITING